Sherif Kamal’s Post

🌟 Efficacy and Safety of SGLT2 Inhibitors With and Without GLP-1 Receptor Agonists 🌟 A recent meta-analysis published in The Lancet Diabetes & Endocrinology explores the efficacy and safety of SGLT2 inhibitors, with or without GLP-1 receptor agonists (GLP-1 RAs). The results are promising for patients with diabetes, cardiovascular, and kidney conditions. 🔍 Case Study: Patient Profile: Name: David Age: 60 Diagnosis: Type 2 Diabetes with Cardiovascular Disease Current Treatment: SGLT2 inhibitor + GLP-1 RA Outcome: Reduced risk of major adverse cardiovascular events (MACE) Decreased hospitalizations for heart failure Slowed progression of chronic kidney disease Discussion Questions: What are the main benefits of combining SGLT2 inhibitors with GLP-1 RAs in managing type 2 diabetes? How do SGLT2 inhibitors improve cardiovascular outcomes in patients with diabetes? What considerations should be made when prescribing these medications together? Interactive Q&A: Q1: How do SGLT2 inhibitors reduce the risk of major adverse cardiovascular events (MACE)? A1: SGLT2 inhibitors reduce MACE by improving glycemic control, lowering blood pressure, and promoting natriuresis, which collectively reduce cardiovascular stress. Q2: Are there any specific patient populations that benefit the most from the combination of SGLT2 inhibitors and GLP-1 RAs? A2: Patients with type 2 diabetes who have a high risk of cardiovascular disease or existing cardiovascular conditions benefit significantly from this combination therapy. Poll: Which outcome is most important to you when choosing a diabetes medication? Cardiovascular protection Kidney health Blood sugar control Weight management Call to Action: 🔗 Learn more about the study here and join our live Q&A session with Dr. Priyadarshini Balasubramanian on the benefits of SGLT2 inhibitors and GLP-1 RAs in diabetes management. Don’t miss this opportunity to get your questions answered! 📈 Success Stories: Success Story 1: Name: Emma Age: 58 Outcome: Emma saw a significant reduction in cardiovascular risk and improved kidney function after starting a combination of SGLT2 inhibitors and GLP-1 RAs. She feels more energetic and healthier than ever! Success Story 2: Name: Mark Age: 65 Outcome: Mark, who struggled with frequent heart failure hospitalizations, experienced fewer hospital visits and improved heart function since starting SGLT2 inhibitors with GLP-1 RAs. Hashtags: #DiabetesManagement #SGLT2Inhibitors #GLP1RAs #CardiovascularHealth #KidneyHealth #TheLancet #MedicalResearch #Endocrinology #PatientCare References: Priyadarshini Balasubramanian, MD. "Efficacy and Safety of SGLT2 Inhibitors With and Without GLP-1 Receptor Agonists." The Lancet Diabetes & Endocrinology. Stay informed and be part of the conversation! 🌐

Exciting developments in the use of #GLP1 receptor agonists (#GLP1RAs) are making waves in both #diabetes management and #weightloss. However, their impact on the gastrointestinal (GI) tract and endoscopic procedures warrants attention. Recent studies have highlighted that while GLP-1RAs like semaglutide and liraglutide offer significant benefits, they are associated with increased risks of GI adverse events, including nausea, vomiting, and pancreatitis, as pointed out in this review published in The Lancet Gastroenterology & Hepatology. These effects are particularly notable during the initiation and titration phases of treatment. One key finding is the delayed gastric emptying induced by GLP-1RAs, which can complicate endoscopic procedures. This delay necessitates careful planning and consideration for patients undergoing such treatments to ensure accurate and safe outcomes. Another paper published in the Red Journal further elaborates on these complications, linking GLP-1RA use with increased GI adverse events observed during endoscopies. This highlights the need for gastroenterologists to be aware of these potential risks and adjust their endoscopic approach accordingly. https://lnkd.in/d8dQH_cb As we continue to explore the full potential of GLP-1RAs, it's crucial for healthcare providers to balance their therapeutic benefits with these GI risks to optimize patient care.

Attempt to gain an additional approval to treat #heartfailure patients with obesity drug Wegovy has been put on hold. Since the studies were "reasonably small," the FDA wanted to see an increase in the number of total cardio events to substantiate the effect of treatment with semaglutide. In March of this year, Wegovy was approved to reduce the risk of cardiovascular events in adults with established heart disease who are obese or overweight. #pharmacy #medicationmanagement #pharma #managedcare #medicine #cardiology #endocrinology

The Future of Cardiovascular Health: How Cyclodextrins are Paving the Way for Atherosclerosis Treatment Atherosclerosis is one of the leading causes of cardiovascular disease, a silent threat that continues to claim millions of lives globally. For years, the focus has been on lowering cholesterol and managing symptoms, but what if we could go beyond that? Enter cyclodextrins—a promising new frontier in the battle against atherosclerosis. For those unfamiliar, cyclodextrins are fascinating molecules that can form complexes with cholesterol. This gives them the potential to not only solubilize but also remove cholesterol from arterial tissues. But their true potential goes far beyond clearing cholesterol. Take the research of Eicke Latz, for example, whose pioneering work has revealed how cyclodextrins reduce cholesterol crystal-induced inflammation. By modulating complement activation and reducing the deposition of inflammatory molecules, cyclodextrins don’t just clear cholesterol; they address the root cause of inflammation that fuels the progression of atherosclerosis. It’s not just theory. Cyclarity Therapeutics is already working on cyclodextrin-based treatments, targeting the notorious 7-ketocholesterol, and early data shows significant reductions in plaque size and improved arterial health. Similarly, Beren Therapeutics is looking at the anti-inflammatory potential of cyclodextrins to stabilize plaques and prevent them from rupturing. And let’s not forget Atherocare, which is using cyclodextrins to enhance cholesterol removal from the cells that contribute to plaque buildup. These innovations are a step closer to a future where cardiovascular disease is more effectively treated, not just managed. The potential is huge, but we're only at the beginning of what could be a revolution in cardiovascular care. Stay tuned—over the coming weeks, we’ll dive deeper into the role of cyclodextrins in tackling other diseases. https://lnkd.in/gcK_79UZ

Interesting in Nature Communications: The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis https://lnkd.in/e2JX54MD Lanifibranor, a pan-PPAR agonist, improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH), who have poor cardiometabolic health (CMH) and cardiovascular events as major mortality cause. NATIVE trial secondary and exploratory outcomes (ClinicalTrials.gov NCT03008070) were analyzed for the effect of lanifibranor on IR, lipid and glucose metabolism, systemic inflammation, blood pressure (BP), hepatic steatosis (imaging and histological grading) for all patients of the original analysis. With lanifibranor, triglycerides, HDL-C, apolipoproteins, insulin, HOMA-IR, HbA1c, fasting glucose (FG), hs-CRP, ferritin, diastolic BP and steatosis improved significantly, independent of diabetes status: most patients with prediabetes returned to normal FG levels. Significant adiponectin increases correlated with hepatic and CMH marker improvement; patients had an average weight gain of 2.5 kg, with 49% gaining ≥2.5% weight. Therapeutic benefits were similar regardless of weight change. Here, we show that effects of lanifibranor on liver histology in MASH are accompanied with CMH improvement, indicative of potential cardiovascular clinical benefits.

🔬 Michigan Medicine's Division of Metabolism, Endocrinology and Diabetes (MEND) is uncovering the secrets behind beta cells in collaboration with Caswell Diabetes Institute (CDI). Beta cells are a crucial component within the pancreas, responsible for producing insulin and regulating blood sugar levels. 🩸 By delving into the intricacies of beta cells, the CDI Islet Program experts aim to advance diabetes research and develop groundbreaking therapies. 💡 Read the article to discover how this research is advancing diabetes therapies: https://lnkd.in/gdBbYi7M #DiabetesResearch #BetaCells #MedicalBreakthroughs #MichiganMedicine

Clinically Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) with Related Factors Hiroshi Bando* #Asploro Journal of Biomedical and Clinical Case Reports ISSN: 2582-0370 Article Type: #Commentary DOI: https://lnkd.in/gTh-Ewus HTML: https://lnkd.in/gza-GiEX Abstract Type 2 diabetes (T2D) is a crucial disease, and glucagon-like peptide 1 receptor agonists (GLP-1RA) have become prevalent as effective oral hypoglycemic agents (OHA). GLP-1RA has clinical effects such as improving glucose variability, reducing weight, and decreasing the risk of cardiovascular disease (CVD). However, recent problems include discontinuation, dropout, and incomplete adherence to GLP-1RA. The discontinuation rates of GLP-1RA were 26.2%, 30.8%, and 36.5% at 3, 6, and 12 months, respectively, and increased to 50.3% for obese patients without T2D. Discontinuation was significantly higher for patients with heart failure (odds ratio 1.09) and CVD (1.08), but not for those with CKD (1.03). #Type2Diabetes, #GlucagonLikePeptide1ReceptorAgonists, #OralHypoglycemicAgent, #ProportionofDaysCovered, #GlucagonLikePeptide, #TokushimaUniversity

The incidence of MASLD in patients who have Type-2 Diabetes is an estimated 45% to 70%. (1)(2) Here is a study that reveals a biomarker that may have utility in identifying MASLD in this patient population (Lead Author: Almir Fajkic) "This was a prospective study for T2DM patients in the prediction of MASLD development based on the adiponectin and resistin levels, where the resistin level in T2DM with MASLD was used for the first time. Both adiponectin and resistin were related to MASLD development in T2DM patients, while resistin was proven to be a biomarker with high sensitivity and specificity for MASLD development. Our data suggest that the adipocytokines represent predictive biomarkers to foresee the MASLD pathogenesis in T2DM patients. Based on the above, ongoing research must combine those adipokines." Key Takeaways: 1. Adiponectin and Resistin as Predictive Biomarkers: The study underscores the importance of adiponectin and resistin as independent predictors of MASLD in T2DM patients. Adiponectin levels inversely correlate with MASLD risk, whereas resistin levels directly correlate, highlighting their potential utility in early diagnosis and intervention. 2. High Sensitivity and Specificity of Resistin: Resistin emerged as a highly accurate biomarker for MASLD development, with an impressive area under the curve (AUC) of 0.997, 96.1% sensitivity, and 100% specificity at the optimal cut-off point. This suggests that resistin could be an invaluable tool in identifying T2DM patients at high risk of developing MASLD. 3. Adiponectin/Resistin (A/R) Index: Significant differences in the A/R index between T2DM individuals with and without MASLD underscore its potential as an additional tool for assessing MASLD risk, further enriching the diagnostic landscape alongside traditional biomarkers. 4. Implications for Clinical Practice: By demonstrating the predictive value of adiponectin and resistin levels for MASLD among T2DM patients, this study paves the way for improved early detection and preventive strategies. It calls for ongoing research to explore the integration of these biomarkers into routine clinical assessments, potentially enabling targeted interventions to mitigate MASLD progression in this high-risk group. 5. This research offers promising insights into the predictive potential of adiponectin and resistin for MASLD in patients with T2DM. https://lnkd.in/g73g-Dbt References: 1. Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials. 2014;9(3):126–33. 2. Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis. 2015;47(12):997–1006.

Interesting results on this important topic